| Similar Articles |
|---|
 |
The Motley Fool
January 11, 2010
Brian Orelli |
Celgene Revs Up for a New Year Preliminary 2009 sales released at the J.P. Morgan Health Care Conference have sales up about 20% year over year and Celgene is guiding for 20% revenue growth next year as well.   |
The Motley Fool
April 28, 2011
Brian Orelli |
Celgene Gets No Love The market shrugs off a solid quarter. |
The Motley Fool
October 23, 2009
Brian Orelli |
Not 50% Growth, but We'll Take It Double-digit growth is still pretty good for Celgene. |
The Motley Fool
July 24, 2009
Brian Orelli |
Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday? |
The Motley Fool
May 8, 2007
Brian Lawler |
Unstoppable Celgene The biotech powerhouse continues its strong financial results as Revlimid sales grow. |
The Motley Fool
October 30, 2006
Brian Lawler |
Celgene: Drug Kingpin Trading at 129 times trailing-12-month adjusted earnings, the biopharmaceutical looks ridiculously expensive, until one considers its awesome sales and earnings growth in that time period. Investors, take note. |
The Motley Fool
April 1, 2009
Brian Orelli |
Conservative Celgene's Conundrum The drugmaker said it expected to make the low end of its previous guidance ranges for non-GAAP revenue and earnings per share for the year. It's not bad news, but it hurt the company nonetheless. |
The Motley Fool
January 30, 2009
Brian Orelli |
Celgene's Double Take Still Looks Good No one is going to stop using Celgene's cancer-fighting products just because the economy is in the tank, so the company should have no problem hitting or even exceeding its growth estimates the way it has before. |
The Motley Fool
January 29, 2010
Brian Orelli |
Wake Up! You Still Have to Pay Attention We already knew Celgene's preliminary numbers, but the conference call offers a look ahead. |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
The Motley Fool
December 8, 2010
Brian Orelli |
Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs. |
The Motley Fool
July 29, 2010
Brian Orelli |
This Best Biotech Is Cheaper Than You Think The cancer-drug specialist justifies its valuation quite effectively with a stellar second-quarter performance. |
The Motley Fool
April 30, 2010
Brian Orelli |
New CEO, Same Old Double-Digit Increases Another strong quarter from Celgene. |
The Motley Fool
February 6, 2007
Brian Lawler |
Celgene Mints the Green Stuff Biotech firm Celgene reports its 2006 financial results and provides an update for its 2007 guidance. Biopharma investors know it's not the past that matters the most in this sector; it's the outlook. |
The Motley Fool
June 8, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Is Celgene the new Genentech? Maybe not -- but it's cheap. |
The Motley Fool
December 9, 2009
Brian Orelli |
Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little. |
The Motley Fool
December 8, 2009
Brian Orelli |
Early and Often: A Drug Investor's Dream Celgene has two goals for its multiple myeloma drug, Revlimid: to have patients begin taking it earlier in the progression of their disease, and to have them stay on the drug longer. |
The Motley Fool
November 20, 2007
Brian Orelli |
Celgene Buys a Sales Force Pharmaceutical Celgene acquires Pharmion for $2.9 billion, hoping that Pharmion's two drugs in mid-to-late clinical trials will justify the purchase price in the not-too-distant future. |
The Motley Fool
December 11, 2008
Brian Orelli |
ASH Wrap-Up: Alphabet Soup and Drugs Let's take a look at the data that came out of the American Society of Hematology meeting regarding pharmaceutical companies' medications for blood diseases. |
The Motley Fool
January 28, 2011
Brian Orelli |
Celgene Needs a Rocket Ship Celgene really needs a hit from Abraxane and other drugs it may license or purchase. |
The Motley Fool
June 9, 2010
Brian Orelli |
ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology. |
The Motley Fool
January 11, 2011
Brian Orelli |
An Undeserved Kick in the Pants Celgene gets knocked around. |
The Motley Fool
January 31, 2008
Brian Lawler |
Prioritizing Millennium The FDA grants a speedy review for Millennium Pharmaceuticals's lead multiple myeloma drug. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
The Motley Fool
October 12, 2009
Brian Orelli |
Onyx Strikes Gold A nice pipeline pickup for this pharmaceutical company. |
The Motley Fool
March 31, 2009
Brian Orelli |
A Good Start for a Potential Blockbuster Novartis' FDA approval for Afinitor is nice, but it needs another indication to be a blockbuster. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
The Motley Fool
December 14, 2006
Brian Lawler |
Celgene Faces a Generic Challenge An abbreviated application is only an opening salvo in Barr's challenge to Celgene's Thalomid patents. Investors, take note. |
The Motley Fool
October 30, 2006
Brian Lawler |
Millennium Is So Last Century The drug company released its third-quarter results last week, and there is not much particularly exciting therein. None of its drug candidates is in late-stage testing and all are years away from approval, except for follow-on indications for Velcade. Investors, take note. |
The Motley Fool
April 24, 2009
Brian Orelli |
The Economy Strikes Again Amgen isn't recession-proof either. |
The Motley Fool
October 6, 2010
Brian Orelli |
Celgene Is All Grown Up An acquirer is on the prowl. |
The Motley Fool
January 5, 2012
Brian Orelli |
Are These Biotech Drug Launches Back on Track? With the annual health-care conference starting up next week, Dendreon and InterMune announced preliminary fourth-quarter sales today. |
The Motley Fool
July 26, 2010
Brian Orelli |
Up 20%! Guess That Hedge Wasn't Needed Onyx reports positive data for its recently acquired multiple myeloma drug. |
The Motley Fool
September 30, 2011
Brian Orelli |
We Don't Care if It's the First Lupus Drug in 50 Years The U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look For With Seattle Genetics in 2012 The launch of its new drug Adcetris will be key. |
The Motley Fool
November 4, 2011
Luke Timmerman |
Celgene to Pump $45M Into Quanticel to Discover Cancer Drugs Celgene strikes an unusual agreement. |
The Motley Fool
December 7, 2009
Brian Orelli |
When the Big Guns Come In, You Get Blasted Larger drug companies may want to gobble up smaller drug firms like Allos Therapeutics and Gloucester Pharmaceuticals. |
The Motley Fool
May 24, 2010
Brian Orelli |
ASCO Abstracts -- Pops and Drops! Ever since The American Society of Clinical Oncology began posting abstracts on-line -- and before that when they were sent to attendees -- investors have clamored to get a glimpse at the data. Here's your glimpse. |
The Motley Fool
March 27, 2009
Brian Orelli |
Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
December 12, 2011
Brian Orelli |
FDA Irony: Less Data, Longer Review Poor Onyx Pharma. |
The Motley Fool
June 30, 2010
Brian Orelli |
Celgene Jumps on a Platform Investors don't seem too enamored with Celgene's announcement that it's purchasing fellow cancer drugmaker Abraxis Bioscience although it looks like a good move in the long term. |
The Motley Fool
August 21, 2008
Brian Lawler |
PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer. |
The Motley Fool
March 26, 2008
Brian Lawler |
Celgene Brings in an Orphan The Food and Drug Administration grants a Celgene drug orphan designation. Amrubicin may have an easier time in development for use in a limited patient population. |
The Motley Fool
December 20, 2010
Brian Orelli |
A Good Fit. On the Surface. Digging a little deeper into Gilead's acquisition of Arresto. |
Chemistry World
July 29, 2015
Phillip Broadwith |
Celgene to buy immune-inflammatory specialist Receptos The deal gives Celgene access to Receptos's pipeline of inflammation and immunology treatments. |
The Motley Fool
February 16, 2007
Brian Lawler |
The Biotech Academy Awards Investors, here are some biotech Oscars for last year's performances: The Biotech Best Picture award -- Celgene... The Biotech Best Drama -- Elan and BiogenIdec... etc. |
The Motley Fool
March 23, 2005
John Reeves |
Stock Madness 2005: Lloyds TSB vs. Celgene Backgrounds on two stocks you might want to consider: Lloyds and Celgene. |
BusinessWeek
May 12, 2011
Robert Langreth |
Big Pharma Bets on a Novel Cancer Cure Research in epigenetics is booming. The payoff could be in the billions. |
The Motley Fool
February 23, 2011
Brian Orelli |
Gilead Gears Up to Fight Cancer Gilead has been infected by the diversification bug. |
